Princeton, MN, United States of America

Daniel Charles Voce

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Microoptx Inc.. Active years: 2021.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations in Ocular Drug Delivery by Daniel Charles Voce

Introduction

Daniel Charles Voce is an accomplished inventor based in Princeton, MN (US). He has made significant contributions to the field of ocular drug delivery systems. His innovative work focuses on developing implantable devices that enhance therapeutic delivery to the eye.

Latest Patents

Voce holds a patent for "Implantable ocular drug delivery devices and methods." This patent describes an implantable ocular drug delivery system that involves inserting a device into the eye. The device is designed to release therapeutics for local or systemic effects. Notably, some embodiments of the device include a microchannel aimed at reducing intraocular pressure, while others are intended to treat dry eye.

Career Highlights

Voce is associated with Microoptx Inc., a company dedicated to advancing ocular health through innovative technologies. His work at Microoptx Inc. has positioned him as a key player in the development of cutting-edge ocular therapies.

Collaborations

Voce collaborates with Edward Aaron Cohen, contributing to the advancement of ocular drug delivery technologies. Their combined expertise enhances the potential for innovative solutions in this critical area of healthcare.

Conclusion

Daniel Charles Voce's contributions to ocular drug delivery represent a significant advancement in medical technology. His innovative patent and work at Microoptx Inc. highlight the importance of research and development in improving patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…